Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research
Despite the very large number of phytocannabinoids isolated from Cannabis (<i>Cannabis sativa</i> L.), bioactivity studies have long remained focused on the so called “Big Four” [Δ<sup>9</sup>-THC (<b>1</b>), CBD (<b>2</b>), CBG (<b>3</b>)...
Main Authors: | Diego Caprioglio, Hawraz Ibrahim M. Amin, Orazio Taglialatela-Scafati, Eduardo Muñoz, Giovanni Appendino |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/8/1084 |
Similar Items
-
The Combined Effect of Branching and Elongation on the Bioactivity Profile of Phytocannabinoids. Part I: Thermo-TRPs
by: Daiana Mattoteia, et al.
Published: (2021-08-01) -
Cannabinol: History, Syntheses, and Biological Profile of the Greatest “Minor” Cannabinoid
by: Chiara Maioli, et al.
Published: (2022-10-01) -
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
by: Leontina Elena Filipiuc, et al.
Published: (2021-11-01) -
Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
by: Andrea Valeri, et al.
Published: (2021-10-01) -
The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies
by: Samay Prakash, et al.
Published: (2021-11-01)